Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.

ABSTRACT:

Objective

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP-1RAs have not been well studied in patients with rheumatoid arthritis (RA). We examined the effects of GLP-1RAs on RA disease activity and cardiovascular risk profile in patients with RA and overweight or obesity.

Methods

We conducted a retrospective chart review study of patients with RA with a body mass index of ≥27 who were prescribed a GLP-1RA (semaglutide or tirzepatide). Between 2018 and 2024, 173 patients with RA were identified in the treatment group (prescribed and took a GLP-1RA), and 42 patients with RA were identified in the control group (prescribed but did not take GLP-1RA). Patients were assessed

SUBMITTER: Kellner DA 

PROVIDER: S-EPMC12423941 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature